The SITI Laboratory (Suivi Immunologique des Thérapeutiques Innovantes) brings together the technical, scientific and medical expertise essential for the development and implementation of innovative biological strategies required for the development of clinical or translational research projects in immunology. The laboratory is an INSERM/EFS/CHU mixed structure, based on a strong partnership in terms of financial as well as human resources, governed by a collective agreement.
The SITI goals are to assist researchers in their innovative therapeutic cancer and non-cancer projects through the implementation of novel biological strategies for patient characterization and monitoring, essential to the understanding of the mechanisms of actions of new therapeutic approaches and to the development of new relevant clinical protocols suited to the clinico-biological characteristics of each patient (personalized medicine).

Clinical research

The SITI laboratory implements the immuno-monitoring of often multicentric and international clinical trials that focus on innovative therapies related to the immune system. The aim is to dissect the impact of those therapies on the immune system, as well as the relationship between the immune state of the patient and the stage of the disease or the effectiveness of the response to the treatment, as a means to better adapt the proposed treatments.

The list of the clinical trials  currently monitored by the SITI can be consulted here.

SITI Laboratory

Translational research

The SITI laboratory conducts translational research through several projects in immunology at the interface between fundamental research and clinical research. The long-term goal is to lead to a personalized therapy that is well adapted to the biological characteristics specific of each patient. Translational projects are carried out around our three research axes :

  • the study of the molecular mechanisms of novel anti-tumor therapies in lymphomas,
  • the analysis of the factors that have an impact on the immunosuppressive properties of mesenchymal stromal cells, in order to improve the treatment of pathologies related to an excessive activation of the immune system,
  • the exploration of the immunosuppressive mechanisms responsible for the overexposure of hospitalized ICU patients (Intensive care Unit) to nosocomial infections.